Dual inhibition of MEK and p38 impairs tumor growth in KRAS-mutated non-small cell lung cancer

Despite the high frequency of KRAS mutations in non-small cell lung cancer (NSCLC), therapeutic modalities targeting KRAS-mutated NSCLC have not been established. Based on our previous findings that mutant KRAS knockdown sensitized NSCLC cells to a p38 inhibitor, the growth-inhibitory effect of dual...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Sunaga, Noriaki, Miura, Yosuke, Tsukagoshi, Yusuke, Kasahara, Norimitsu, Masuda, Tomomi, Sakurai, Reiko, Kaira, Kyoichi, Hisada, Takeshi
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2019
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6396226/
https://ncbi.nlm.nih.gov/pubmed/30867799
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10009
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars